Anemia

Everything

Sangart
www.sangart.com
Skip to content Sangart Company History Management Team Board of Directors Investor Relations Business Development Career Opportunities Products MP4OX MP4CO Pipeline Research Trauma Sickle Cell Anemia Other Conditions Clinical Trials Relevant Literature Newsroom Contact Aiming to provide patients

Home - FibroGen, Inc.
www.fibrogen.com
Fibrogen, Inc. About Us Company Overview Leadership Investors Strategic Alliances Contacts FibroGen Europe Clinical Current Trials Research & Development Hypoxia-Inducible Factor HIF Biology HIF-PHI Therapy Anemia Cytoprotection/Inflammation Connective Tissue Growth Factor CTGF Biology Anti-CTGF

Affymax, Takeda submit new drug application for anemia treatment | Pharma Asia
www.pharmaasia.com | Jun 1, 2011
Affymax Inc and Takeda Pharmaceutical Company Limited announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA). This is for the investigational agent peginesatide (formerly known as Hematide) for the treatment of anemia associated with chronic renal

Anemia - Drug Pipeline Analysis and Market Forecasts to 2016
www.prlog.org | May 3, 2010
Anemia - Drug Pipeline Analysis and Market Forecasts to 2016. The Anemia Market is Expected to Witness Marginal Decline Due to Rising Safety Concerns over ESA Therapies and Weak Late-Stage Pipeline

Intravenous Iron Improves Treatment Response in Cancer-related Anemia
www.dddmag.com
Recently present data shows that adding intravenous iron to treatment with the drug darbepoetin alfa results in a faster and more potent improvement in response with lower doses of the drug for patients with chemotherapy-induced anemia.

Identification of clinical and simple laboratory variables predicting responsible gastrointestinal
www.medsci.org | Dec 16, 2011
<p>Iron deficiency anemia (IDA) is a frequent disorder. Also, it may be a sign of underlying serious diseases. Iron deficiency points to an occult or frank bleeding lesion when occurred in men or postmenopausal women. In this study, we aimed to evaluate the diagnostic yield of endoscopy in patients

AFFYMAX AND TAKEDA CONFIRM U.S. REGISTRATION STRATEGY FOR INVESTIGATIONAL DRUG,
www.takeda.com | Nov 29, 2010
PALO ALTO, Calif., and OSAKA, Japan, Nov 29, 2010 – Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE, 4502), today announced that following pre-New Drug Application (NDA) discussions with the U.S. Food and Drug Administration (FDA), the companies will move forward with

ProMetic Signs Terms of Strategic Agreement for PBI-1402 and PBI-4419 With Allist Pharmaceuticals
www.sys-con.com | Oct 19, 2010
SYS-CON Media, NJ, The world's leading i-technology media company on breaking technology news.

P02-266 - Anaemia in elderly in-patients in psychiatric hospitala serious problem or an innocent
www.em-consulte.com
European Psychiatry - Vol. 26 - N° S1 - p. 862 - P02-266 - Anaemia in elderly in-patients in psychiatric hospitala serious problem or an innocent finding? - EM|consulte

July 26, 2010
www.bio-trends.com | Jul 28, 2010
BioTrends: In the renal anemia market, the use of erythropoietin stimulating agents (ESAs) in patients with chronic kidney disease, not on dialysis (CKD-ND) continues to decline with significantly fewer CKD Stage 4 patients on ESAs compared to the prior year.